Interim Phase I/II results for Lexeo's LX2020 show an 80% average drop in dangerous heart-rhythm runs at the higher dose, with heart biopsies showing the missing PKP2 protein restored. The FDA is open to a faster approval path.
Gene editing is moving from rare disease to high cholesterol and high triglycerides. Every Gene Tech Times story on PCSK9 and ANGPTL3 editing, and the argument it starts.